Эффективность и безопасность этелкальцетида по сравнению с цинакальцетом для пациентов, получающих гемодиализ с вторичным гиперпаратиреозом. Результаты проспективного рандомизированного исследования
- Авторы: Шутов Е.В.1,2, Котлярова Г.В.3, Лысенко К.М.3, Рябинская Г.В.3, Лашутин С.В.3, Маркелова И.А.3, Рублева С.Ю.3
-
Учреждения:
- ГБУЗ городская клиническая больница им. С.П. Боткина
- Российская медицинская академия непрерывного профессионального образования
- ГБУЗ ГКБ им. С.П. Боткина ДЗМ
- Выпуск: Том 13, № 2 (2021)
- Страницы: 34-40
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2075-3594/article/view/273760
- DOI: https://doi.org/10.18565/nephrology.2021.2.34-40
- ID: 273760
Цитировать
Полный текст
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Ключевые слова
Полный текст
Об авторах
Евгений Викторович Шутов
ГБУЗ городская клиническая больница им. С.П. Боткина; Российская медицинская академия непрерывного профессионального образованияд.м.н., профессор, руководитель Межокружного нефрологического центра; заведующий кафедрой нефрологии и гемодиализа Москва, Россия; Москва, Россия
Галина Владимировна Котлярова
ГБУЗ ГКБ им. С.П. Боткина ДЗМк.м.н., зав. отделением гемодиализа Москва, Россия
Ксения Марковна Лысенко
ГБУЗ ГКБ им. С.П. Боткина ДЗМврач-нефролог Москва, Россия
Галина Владимировна Рябинская
ГБУЗ ГКБ им. С.П. Боткина ДЗМк.м.н., врач-лаборант Москва, Россия
Сергей Витальевич Лашутин
ГБУЗ ГКБ им. С.П. Боткина ДЗМк.м.н., врач-нефролог Москва, Россия
Ирина Анатольевна Маркелова
ГБУЗ ГКБ им. С.П. Боткина ДЗМврач-нефролог Москва, Россия
Светлана Юрьевна Рублева
ГБУЗ ГКБ им. С.П. Боткина ДЗМврач-нефролог Москва, Россия
Список литературы
- Block G.A., Klassen P.S., Lazarus J.M., et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol 2004;15:2208-18.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Working Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009;113(Suppl.):S1-130.
- Wesseling-Perry K, Pereira R.C., Tseng C.H., et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2012;7:146-52.
- Drueke T.B., Massy Z.A. Changing bone patterns with progression of chronic kidney disease. Kidney Int. 2016;89:289-302.
- Graciolli F.G., Neves K.R., Barreto F., et al. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int. 2017;91:1436-46.
- Barker S.L., Pastor J., Carranza D., et al. The demonstration of alphaKlotho deficiency in human chronic kidney disease with a novel synthetic antibody. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2015;30:223-33.
- Nakatani T., Sarraj B., Ohnishi M., et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) - mediated regulation of systemic phosphate homeostasis. FASEB J.: official publication of the Federation of American Societies for Experimental Biology. 2009;23:433-41.
- Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin. J. Am. Soc. Nephrol. 2011;6:913-21.
- Block G.A., Martin K.J., de Francisco A.L., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 2004;350:1516-25.
- Goldsmith D., Covic A., Vervloet M., et al. Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) working group and the European Renal Best Practice (ERBP) advisory board; Chronic Kidney Disease-Mineral Bone Disease CKD-MBD working group and the European Renal Best Practice ERBP advisory board. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol. Dial. Transplant. 2015;30:698-700.
- Ketteler M., Block G.A., Evenepoel P., et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int 2017;92:26- 36. Erratum in: Kidney Int. 2017;92:1558.
- Custodio M.R., Canziani M.E., Moyses R.M., et al. [Clinical protocol and therapeutic guidelines for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease]. J. Bras. Nefrol. 2013;35:308-22. Pharmacology of AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor,for the treatment of secondary hyperparathyroidism in hemodialysis patients. J. Pharmacol. Exp. Ther. 2013;346(2):229-40.
- Block G.A., Bushinsky D.A., Cheng S., et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: A randomized clinical trial. JAMA. 2017;317(2):156-64.
- Block G.A., Bushinsky D.A., Cunningham J., et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA. 2017; 317(2): 146-155.
- Martin K.J., Pickthorn K., Huang S., et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int. 2014;85(1):191-7.
- KDIGO Workgroup. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) 2017 [cited 2018 January 31]. Available from: http://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf.
- Akira Mima, Kosuke Tansho, Dai Nagahara, Kenji Watase Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study. J. Int. Med. Res. 2018;46(11):4578-85.
- Palmer S.C., Mavridis D., Johnson D.W., et al. Comparative Effectiveness of Calcimimetic Agentsfor Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Am. J. Kidney Dis. 2020;76(3):321-30.
- Block G.A., Bushinsky D.A., Cheng S., et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017;317(2):156-64.
- Regidor D.L., Kovesdy C.P., Mehrotra R., et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J. Am. Soc. Nephrol. 2008;19:2193-203.
- Beddhu S., Ma X., Baird B., et al. Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009;4:1805-10.
- Blayney M.J., Pisoni R.L., Bragg-Gresham J.L., et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 2008;74(5):655-63. doi: 10.1038/ki.2008.248.
- Yamashita T., Shizuku J., Ohba T., et al. Serum alkaline phosphatase levels and mortality of chronic hemodialysis patients. Int. J. Clin. Med. 2011;2:388-93.
- Shantouf R., Kovesdy C.P, Kim Y., et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2009;4:1106-14.
- Beige J., Wendt R., Girndt M., et al. Association of serum alkaline phosphatase with mortality in non-selected European patients with CKD5D: an observational, three-centre survival analysis. BMJ. Open. 2014;4(2):e004275.
- Yu Fan, Xin Jin, Menglin Jiang, et al. Elevated serum alkaline phosphatase and cardiovascular or all-cause mortality risk in dialysis patients: A meta-analysis Sci. Rep. 2017;7:13224.
- Moester M.J., Papapoulos S.E., Lowik C.W., et al. Sclerostin: Current knowledge and future perspectives. Calcif. Tissue Int. 2010;87:99-107.
- Khosla S., Westendorf J.J., Oursler M.J. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest. 2008;118:421-8.
- Sato M., Hanafusa N., Kawaguchi H., et al. A Prospective Cohort Study Showing No Association Between Serum Sclerostin Level and Mortality in Maintenance Hemodialysis Patients. Kidney Blood Press. R. 2018;43:1023-33.
- Nowak A., Artunc F, Serra A.L., Pollock E., et al. Is This a Useful Long-Term Mortality Parameter in Prevalent Hemodialysis Patients? Kidney Blood Press R. 2015;40:266-76. doi: 10.1159/000368502.
- Delanaye P., Krzesinski J.M., Warling X., et al. Clinical and Biological Determinants of Sclerostin Plasma Concentration in Hemodialysis Patients. Nephron Clin. Pract. 2014;128:127-34.
- Drechsler C., Evenepoel P., Vervloet M.G., et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: Results from the NECOSAD study. Nephrol. Dial. Transpl. 2015;30:288-93.
- Jean G., Chazot C., Bresson E., Zaoui E., Cavalier E. High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients. Nephron. 2016;132:181-90.
- Wang X.R., Yuan L.A., Zhang J.J., et al. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D. Nephrol. 2017;22:286-92.
- Goncalves F.L.C., Elias R.M., dos Reis L.M., et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC. Nephrol. 2014;15:190. doi: 10.1186/1471-2369-15-190.
- Persy V., D’Haese P. Vascular calcification and bone disease: The calcification paradox. Trends Mol. Med. 2009;15:405-16.
- De Mare A., Maudsley S., Azmi A., et al. Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone-Vascular Axis. Toxins. 2019;11:428.
- Viaene L., Behets G.J., Claes K., et al. Sclerostin: Another bone-related protein related to all-cause mortality in haemodialysis? Nephrol. Dial. Transpl. 2013;28:3024-30.
- Bisson S.K., Ung R.V., Picard S., et al. High calcium, phosphate and calcitriol supplementation leads to an osteocyte-like phenotype in calcified vessels and bone mineralisation defect in uremic rats. J. Bone Miner. Metab. 2019;37:212-23.
- Saag K.G., Petersen J., Brandi M.L., et al. Romosozumab or Alendronate for Fracture Prevent ion in Women with Osteoporosis. N. Engl. J. Med. 2017;377(15):1417-27.
- Isakova T., Wahl P., Vargas G.S., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370-8.
- Poelzl G., Trenkler C., Kliebhan J., et al. FGF23 is associated with disease severity and prognosis in chronic heart failure. Eur. J. Clin. Invest. 2014;44(12):1150-8.
- Wolf M., Block G.A., Chertow G.M., et al. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. Clin. Kidney J. 2020;13(1):75-84.
- Sawires H.K., Essam R.M., Morgan M.F., et al. Serum klotho: relation to fibroblast growth factor-23 and other regulators of phosphate metabolism in children with chronic kidney disease. Nephron. 2015;129(4):293-9.
- Komaba H., Koizumi M., Tanaka H., et al. Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2012;27(5):1967-9.